Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types

 
• By Jung Won Shin, Vibha Ravi, Joseph Haas, and Ian Haydock

RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.

DealWatch_1200x675

More from Deals

More from Business